問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1733Cases

2012-04-01 - 2014-04-30

Phase II

A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    MEDI-546

Participate Sites
1Sites

Study ended1Sites

2008-04-01 - 2010-05-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-01-01 - 2014-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-07-28 - 2018-12-31

Phase II

A multi-center, randomized, double-blind, parallel-group　dose-finding study to assess the effect of 3 doses of　LIK066 compared to placebo or empagliflozin in type 2　diabetes mellitus patients with heart failure

  • Condition/Disease

    type 2　diabetes mellitus patients with heart failure

  • Test Drug

    LIK066

Participate Sites
4Sites

Terminated3Sites

2017-09-21 - 2020-12-31

Phase III

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

  • Condition/Disease

    Advanced Breast Cancer

  • Test Drug

    Ribociclib (LEE011)/ Letrozole/Goserelin

Participate Sites
6Sites

Terminated5Sites

鍾為邦
National Taiwan University Hospital

Division of Hematology & Oncology

邱昌芳
China Medical University Hospital-Taipei

未分科

2014-10-01 - 2016-12-31

Phase II

A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis

  • Condition/Disease

    Polymyositis (PM)

  • Test Drug

    BAF312

Participate Sites
1Sites

Study ended1Sites

藍忠亮
China Medical University Hospital

2014-11-01 - 2019-05-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Condition/Disease

    Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Terminated9Sites

2016-01-01 - 2019-05-31

Phase III

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

  • Condition/Disease

    uncontrolled severe asthma

  • Test Drug

    QAW039

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

許武輝醫師
China Medical University Hospital

Division of Thoracic Medicine

2014-12-01 - 2017-09-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-02-01 - 2020-05-30

Phase III

A 12-week double-blind, randomized, multi-center study comparing the efficacy and safety of once monthly subcutaneous AMG 334 against placebo in adult episodic migraine patients (EMPOwER)

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    AMG334

Participate Sites
9Sites

Terminated8Sites

Study ended1Sites

林剛旭
China Medical University Hospital

羅榮昇
Linkou Chang Gung Medical Foundation

1 151 152 153 154 155 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB